Invented and founded by Tess Fries, Elixira is a next-generation, patent-pending, AI-guided nanobot platform designed as a one-time injection for lifelong, autonomous prevention across all cancer types. Its technical feasibility has been independently confirmed by a leading Contract Research Organization (CRO), and all core technologies underlyingElixira have been peer-reviewed and validated. A detailed technical feasibility report is available to prospective partners under NDA.
Developed on in vivo–proven nanotechnology and biomedical engineering principles, Elixira integrates self-sustaining energy systems and multiple elimination methods to enable a proactive, continuous prevention model. Operating autonomously inside the human body, it detects, targets, and neutralizes cancer cells in real time — powered entirely by its own renewable energy systems.

Engineered for global scalability, ethical accessibility, and minimal infrastructure requirements, Elixira’s mission is to advance preventive cancer care worldwide — enabling earlier detection, intervention, and improved long-term health outcomes.

Biotechnology

Health Care

Life Sciences

Elixira

Org chart

Teams

Offices

Similar companies